A Healthy Volunteer Study to Compare Fezagepras (PBI-4050) With Sodium Phenylbutyrate
Status:
Not yet recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety, tolerability and pharmacokinetic profile
of fezagepras (PBI-4050) to that of sodium phenylbutyrate (PBA) when both products are given
as single ascending doses to healthy adult subjects.